Storys aus Cambridge, Massachusetts

09.03.2023 – 13:01
Medison Pharma; Alnylam Pharmaceuticals
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Zug, Switzerland (ots/PRNewswire) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their ...
mehr
26.04.2022 – 14:01
Novaliq GmbH
NOVALIQ PRESENTS DATA FROM SECOND PHASE 3 TRIAL OF INVESTIGATIONAL TREATMENT CYCLASOL® (0.1% CYCLOSPORINE OPHTHALMIC SOLUTION) AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING
Heidelberg, Germany, and Cambridge, Mass. (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that data from the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational ...
mehr
21.12.2021 – 14:00
Novaliq GmbH
Novaliq Announces POSITIVE Topline Results for SECOND PHASE 3 TRIAL (ESSENCE-2) of CyclASol® in Dry Eye Disease
Heidelberg, Germany and Cambridge, Mass (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug ...
mehr
16.12.2021 – 08:01
Novaliq GmbH
PHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) CONDUCTED BY JIANGSU HENGRUI PHARMACEUTICALS IN THE PEOPLE'S REPUBLIC OF CHINA SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS
Heidelberg, Germany, and Cambridge, Mass. (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the ...
mehr
12.10.2021 – 09:00
Novaliq GmbH
Novaliq Receives EU Quality Management Certificate According To New Medical Device Regulation (MDR)
Heidelberg, Germany (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that it has implemented and applies a quality management system in accordance with Annex IX, Chapter I of the EU ...
mehr
13.07.2021 – 13:00
Abcam plc
Abcam opens new US facility in Boston, MA
Cambridge (ots/PRNewswire) - Supporting accelerated growth of R&D, manufacturing, and commercial activities with new 100,000 sq-ft state-of-the-art facility Reinforcing commitment to the region as Abcam approaches 20 years of US presence Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences reagents and tools, today announces the opening of a major new site in Waltham, MA. The new facility is a central ...
mehr
10.05.2021 – 08:01
Avectas
Avectas announces publication in leading cell therapy journal Cytotherapy of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications'
Dublin (ots/PRNewswire) - SOLUPORE® technology enables the next-generation of gene-modified cell therapies Irish based cell engineering company, Avectas today announces the publication of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy ...
mehr
08.12.2020 – 14:00
Novaliq GmbH
Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease
Heidelberg, Germany (ots/PRNewswire) - - ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol® as agreed with U.S. Food and Drug Administration (FDA) - Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial - Topline data expected in 2nd half 2021 ...
mehr
17.11.2020 – 14:01
Sophia Genetics
Bram Goorden joins SOPHiA GENETICS as Chief Commercial Officer and Head of North America
Boston and Lausanne, Switzerland (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Bram Goorden joined its Executive team, holding the dual role of Chief Commercial Officer and Head of North America. Goorden comes to SOPHiA from Foundation Medicine Inc. (Cambridge, MA) where he held the role of VP of International Business and ...
mehr
13.07.2020 – 20:03
Merck Healthcare Germany GmbH
Stephan Sieber Awarded EUR 1 Million Future Insight Prize 2020 by Merck
Darmstadt, Germany (ots/PRNewswire) - - Prof. Sieber is developing approaches against multi-resistant pathogens at the Technical University of Munich - Inaugural Johann Anton Merck Award presented to Prof. Caroline Dive, Cancer Research UK, for her liquid biopsy research - Sibel Health awarded the Nature Spinoff Prize Merck, a leading science and technology company, ...
mehr
02.04.2020 – 15:35
UCB Pharma
UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
Brussels (ots/PRNewswire) - - The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab , UCB's FcRn targeting ...
mehr
10.10.2019 – 09:38
UCB Pharma
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - Will enrich UCB's pipeline; zilucoplan is a novel, ...
mehr
24.01.2019 – 14:01
Merck Healthcare Germany GmbH
Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas - Merck retains the rights to both compounds in all other disease areas, including oncology - Merck retains the rights to utilize and ...
mehr
19.03.2014 – 10:02
Hult International Business School
Survey of Senior Business Leaders Reveals Ongoing Deficit of Job-Ready MBA Grads
Cambridge, Massachusetts (ots/PRNewswire) - Hult International Business School Report Highlights Business Schools' Failure to Modernize in Response to Technological, Economic, and Societal Change Hult International Business School today released a report entitled "The Future of Business Education & the Needs of Employers." Hult Labs, the school's internal think tank, ...
mehr